Lung Cancer: a rapidly changing landscape


This study day will provide an update on novel therapies and approaches to the management of Non Small Cell Lung Cancer.

  • Lung screening and early detection - emerging technologies
  • Lung cancer stream in Prehab4Cancer programme
  • Exploring the treatment modalities for NSCLC
  • Social aspect of living with lung cancer and the psychological impact of remission

Suitable for Nurses, Allied Health Professionals and all Clinicians with an interest in lung cancer

Gold sponsors

For more than a century, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases.

Today, MSD continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world.

For more information, visit the MSD website and connect with MSD by following @MSDintheUK on Twitter, Instagram, LinkedIn, YouTube and Facebook.

Takeda Oncology endeavour to deliver novel medicines to cancer patients worldwide through their commitment to science, breakthrough innovation and passion for improving the lives of patients.

This singular focus drives their aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the resources of a global pharmaceutical company, Takeda Oncology are finding innovative ways to improve the treatment of cancer.

Takeda Oncology have built a portfolio of paradigm changing therapies and a leading oncology pipeline. Though they’ve made great strides in their fight against cancer, they are determined to do more – to work harder and to reach higher. Takeda Oncology continue to seek their aspirations with the same passion, agility and entrepreneurial spirit that has sustained their patient-centric culture and has made them the innovators in oncology they are today.

They know their mission is not a quick or simple one, but Takeda Oncology are up for the task: they aspire to cure cancer.

Silver sponsors

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit the Amgen website and follow @amgen on Twitter.

Roche is a pioneer in pharmaceuticals and diagnostics, focused on advancing science to improve people’s lives. They have created truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system.

In the UK, Roche employ over 2,000 people who work hard every day to bring their medicines and diagnostics to people who urgently need them. They work from bench to bedside - researching new medicines and diagnostics, running global clinical trials, and collaborating with the NHS to try to ensure rapid uptake and delivery of their products and services.

In 2017, Roche's total research and development investment in the UK amounted to £338 million and they conducted over 181 clinical trials with 10,600 participants. In 2018, they worked with NICE and NHS England to ensure 8 of their new treatments were made available on the NHS. Roche's drive, every day, is to ensure their medicines reach those who need them as soon as possible. For more information, visit the Roche website.

If you are interested in sponsoring this event please contact us via email.

Click here to be kept up to date with this and future events

Last updated: September 2020